T CELL LYMPHOMA
Clinical trials for T CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new T CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for T CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Lymphoma drug duvelisib tested after transplant – trial ends early
Disease control TerminatedThis phase 2 trial tested the drug duvelisib (Copiktra) as a maintenance therapy after an autologous stem cell transplant in 17 people with T-cell lymphoma. The goal was to see if it could safely delay the cancer from coming back. The study was terminated early, so the full resul…
Matched conditions: T CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Early trial of tazemetostat for tough T-Cell lymphoma halted after just 6 patients
Disease control TerminatedThis early-phase study tested the safety of a drug called tazemetostat in people with a type of blood cancer called peripheral T-cell lymphoma that had returned or stopped responding to other treatments. Only 6 participants were enrolled before the study was stopped early. The go…
Matched conditions: T CELL LYMPHOMA
Phase: PHASE1 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Immunotherapy combo after transplant shows promise for High-Risk blood cancers
Disease control TerminatedThis study tested whether giving two immunotherapy drugs (nivolumab and ipilimumab) after a stem cell transplant could safely help control high-risk multiple myeloma and lymphoma. It involved 46 adults aged 18-80 whose cancer was at high risk of coming back. The main goal was to …
Matched conditions: T CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Hackensack Meridian Health • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC